Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice
- PMID: 1692259
Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice
Abstract
Fifty-nine transgenic mice from a lineage that overproduces the hepatitis B virus large envelope polypeptide and accumulates high intrahepatic concentrations of hepatitis B surface antigen were followed for evidence of liver disease throughout their 24-month life span. By 4 months of age all mice displayed biochemical and histological evidence of moderately severe chronic hepatitis which was followed sequentially by the development of regenerative nodules and oval cell hyperplasia (by 6 months), liver cell adenomas (by 8 months), and hepatocellular carcinomas (by 12 months of age). One hundred % of mice in this lineage developed hepatocellular carcinoma by 20 months of age, whereas no histopathological changes were observed in age- and sex-matched nontransgenic littermate controls over the same period of observation. These results indicate that overproduction of the hepatitis B virus large envelope polypeptide initiates a process characterized by liver cell injury, inflammation, and regenerative hyperplasia, which places large numbers of hepatocytes at risk for the development of transforming mutations, and inexorably progresses to hepatocellular carcinoma. We suggest that this is a general mechanism of hepatocarcinogenesis that may be operative in human hepatitis B virus infection and other necroinflammatory liver diseases as well.
Similar articles
-
Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice.Cancer Res. 1991 Feb 15;51(4):1278-85. Cancer Res. 1991. PMID: 1847661
-
Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice.Hepatology. 1995 Mar;21(3):620-6. Hepatology. 1995. PMID: 7875658
-
Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice.Cell Growth Differ. 1992 Aug;3(8):531-40. Cell Growth Differ. 1992. PMID: 1356418
-
[Hepatitis and hepatocarcinogenesis in the transgenic mice].Nihon Rinsho. 1993 Feb;51(2):531-5. Nihon Rinsho. 1993. PMID: 8464165 Review. Japanese.
-
Transgenic mouse models of hepatitis B virus-associated hepatocellular carcinoma.Rev Med Virol. 2003 Jul-Aug;13(4):243-53. doi: 10.1002/rmv.392. Rev Med Virol. 2003. PMID: 12820186 Review.
Cited by
-
Study on the hepatocellular carcinoma model with metastasis.Genes Dis. 2020 Jan 8;7(3):336-350. doi: 10.1016/j.gendis.2019.12.008. eCollection 2020 Sep. Genes Dis. 2020. PMID: 32884988 Free PMC article. Review.
-
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.Am J Pathol. 2002 Jun;160(6):2295-307. doi: 10.1016/S0002-9440(10)61177-7. Am J Pathol. 2002. PMID: 12057932 Free PMC article.
-
A novel non-toxic xylene substitute (SBO) for histology.Afr J Tradit Complement Altern Med. 2011 Oct 2;9(1):43-9. doi: 10.4314/ajtcam.v9i1.6. eCollection 2012. Afr J Tradit Complement Altern Med. 2011. PMID: 23983318 Free PMC article.
-
Mouse models for liver cancer.Mol Oncol. 2013 Apr;7(2):206-23. doi: 10.1016/j.molonc.2013.01.005. Epub 2013 Feb 5. Mol Oncol. 2013. PMID: 23428636 Free PMC article. Review.
-
BATF Interference Blocks Th17 Cell Differentiation and Inflammatory Response in Hepatitis B Virus Transgenic Mice.Dig Dis Sci. 2019 Mar;64(3):773-780. doi: 10.1007/s10620-018-5392-x. Epub 2018 Nov 29. Dig Dis Sci. 2019. PMID: 30498928
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Molecular Biology Databases